Evaluating the efficacy and safety of bromhexine in hospitalized COVID-19 patients

Shahid Beheshti University of Medical Sciences0 个研究点目标入组 100 人开始时间: 待定最近更新: 2020年11月30日

适应症

试验速览

暂无简介。

•Age =18 years at time of signing Informed Consent Form
•Laboratory (RT-PCR) confirmed infection with COVID-19
•Lung involvement confirmed with chest imaging
•Hospitalized with a SaO2/SPO2=94% on room air or PaO2/FiO2 ratio <300mgHg
•=12 days since illness onset
•Willingness of study participant to accept randomization to any assigned treatment arm
•Must agree not to enroll in another study of an investigational agent prior to completion of Day 28 of study

•Physician makes a decision that trial involvement is not in patients' best interest, or any condition that does not allow the protocol to be followed safely
•Severe liver disease (e.g. Child Pugh score = C, AST>5 times upper limit)
•Pregnant or breastfeeding, or positive pregnancy test
•Patients with known severe renal impairment (estimated glomerular filtration rate =30 mL/min/1.73 m2) or receiving continuous renal replacement therapy, hemodialysis, peritoneal dialysis
•Will be transferred to another hospital which is not the study site within 72 hours
•Receipt of any experimental treatment for 2019-nCoV (off-label, or trial related) within the 30 days prior to the time of the screening evaluation
•Allergic to the Bromhexine

发起方